Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Accumulated Expenses: 2018-2021

Historic Accumulated Expenses for Black Diamond Therapeutics (BDTX) over the last 2 years, with Sep 2021 value amounting to $21.5 million.

  • Black Diamond Therapeutics' Accumulated Expenses rose 161.61% to $21.5 million in Q3 2021 from the same period last year, while for Sep 2021 it was $21.5 million, marking a year-over-year increase of 161.61%. This contributed to the annual value of $11.7 million for FY2020, which is 302.90% up from last year.
  • Per Black Diamond Therapeutics' latest filing, its Accumulated Expenses stood at $21.5 million for Q3 2021, which was up 16.50% from $18.5 million recorded in Q2 2021.
  • In the past 5 years, Black Diamond Therapeutics' Accumulated Expenses ranged from a high of $21.5 million in Q3 2021 and a low of $452,000 during Q4 2018.
  • In the last 3 years, Black Diamond Therapeutics' Accumulated Expenses had a median value of $9.9 million in 2020 and averaged $10.7 million.
  • Data for Black Diamond Therapeutics' Accumulated Expenses shows a peak YoY soared of 541.37% (in 2019) over the last 5 years.
  • Black Diamond Therapeutics' Accumulated Expenses (Quarterly) stood at $452,000 in 2018, then soared by 541.37% to $2.9 million in 2019, then soared by 302.90% to $11.7 million in 2020, then soared by 161.61% to $21.5 million in 2021.
  • Its Accumulated Expenses was $21.5 million in Q3 2021, compared to $18.5 million in Q2 2021 and $14.1 million in Q1 2021.